Cain McClary MDManaging Partner and Founder at KdT Ventures
Cain McClary, MD is the founder and Managing Partner of KdT Ventures, the standard for early-stage science investing. Over the past 10 years, Cain has been at the forefront of the intersection between technology and science, investing and advising companies at the earliest stages who are now collectively valued in excess of $2 Billion. Select investments include Zymergen, PathAI, Dyno Tx, Solugen, Abridge AI, and Firefly Bioworks (Acquired by AbCam). His love of science and investing led Cain to build KdT Ventures, which helps founders and their companies re-architect the world at a molecular level. A native of Nashville, TN, Cain received his Sc.B. in Biochemistry and Molecular Biology from Brown University in 2007. Following Brown, Cain went on to receive his medical degree from Tulane University School of Medicine in 2012. During medical school, Cain also spent a year at the National Institutes of Health (NIH) as part of the prestigious Howard Hughes Medical Institute “Cloister” Fellowship, where he studied the role of non-coding RNA in cancer at the National Cancer Institute (NCI). Immediately following medical school, Dr. McClary underwent residency training in Anatomic Pathology at Stanford University, where during his final year, he was named Chief Resident and appointed as Assistant Professor in the Department of Pathology at Stanford University, becoming the youngest person on faculty in pathology at the time. Currently, Cain holds a faculty position at the Tulane University School of Medicine.